An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
This Phase 2, multi-center, double-blind, randomized, placebo-controlled, parallel group,
add-on study of MLR 1023 in adults with uncontrolled T2DM on metformin anti diabetic
monotherapy is designed to evaluate the efficacy and safety of MLR 1023 in combination with
metformin in subjects with uncontrolled T2DM.